The depletion or accumulation of metabolites in the tumour microenvironment is one of the hallmarks of cancer, but targeting cancer cell metabolism therapeutically must also take into account the impact on metabolic pathways in immune cells. As we understand more about immunometabolism, opportunities arise for synergies between agents that modulate metabolism and immunotherapy. In this Review, we discuss the pivotal role of metabolic pathways in both cancer and immune cells in shaping the tumour microenvironment. We survey major anabolic and catabolic pathways and discuss how metabolic modulators and dietary nutrients can improve the anticancer immune response and overcome drug resistance mechanisms. Agents in the clinic include inhibitors of the adenosine and tryptophan pathways, and we discuss opportunities and challenges for successful drug development in the context of immune checkpoint blockade and chimeric antigen receptor (CAR)-T cell therapies.
Institute(s)Unit for Clinical Pharmacology (KKG-EKLiP)
GrantsIdEx Universit de Paris Bavarian Research Foundation Fritz-Bender Foundation European Research Council Bundesministerium fr Bildung und Forschung Wilhelm-Sander-Stiftung German Cancer Aid Else Krner-Fresenius-Stiftung Horizon Programme of the EU Marie Sklodowska-Curie Training Network for Optimizing Adoptive T Cell Therapy of Cancer - Horizon 2020 programme of the European Union Deutsche Forschungsgemeinschaft (DFG) Dr-Rurainski Foundation Monika Kutzner Foundation SNSF Postdoc.Mobility Fellowship Institut National du Cancer SIRIC SIRIC Cancer Research and Personalized Medicine (CARPEM) European Research Council Advanced Investigator Award Seerave Foundation ANR Agence Nationale de la Recherche (ANR) Agence Nationale de la Recherche under the France European Union Institut National du Cancer (INCa) Ligue contre le Cancer Bavarian Cancer Research Center (BZKF)